Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1436-1442

  MacGowan, Alasdair P ^a   Noel, Alan ^a   Tomaselli, Sharon ^a   Elliott, Heather ^a   Bowker, Karen ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; EXTENDED SPECTRUM BETA LACTAMASE; METICILLIN; RAZUPENEM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM COLONY; CULTURE MEDIUM; ENTEROBACTER; ESCHERICHIA COLI; IN VITRO STUDY; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 79953193774     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00936-10     Document Type: Article

References (19)

1. Andes, D. R., and W. A. Craig. 2006. In vivo pharmacodynamics of a new carbapenem PZ601 against multiple bacteria in murine thigh and lung infection models, abstr. F1-232, p. 1999. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
2. Andrews, J. 1999. Microbiological assays, p. 35-45. In D. S. Reeves, R. Wise, J. M. Andrews, and L. O. White (ed.), Clinical antimicrobial assays. Oxford University Press, Oxford, United Kingdom.
3. Bhavnani, S. M., et al. 2007. Population pharmacokinetic (PKI) and Monte Carlo simulation (MCS) analyses to support phase 3 PZ-601 (SMP-601) dosing strategies for complicated skin and skin structure infection (SSS1), abstr. A-40. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
4. Bowker, K. E., A. R. Noel, and A. P. MacGowan. 2006. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J. Antimicrob. Chemother. 58:802-805.
5. British Society for Antimicrobial Chemotherapy Working Party. 2001. Antimicrobial susceptibility testing. J. Antimicrob. Chemother. 46(Suppl. S1):5-16.
6. Clark, C., et al. 2009. Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillinresistant and two methicillin-susceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53:3118-3121.
7. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Craig, W. A. 2002. Pharmacodynamics of antimicrobials: general concerns and applications, p. 1-22. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.), Antimicrobial pharmacodynamics in theory and practice. Marcel Dekker Inc., Basel, Switzerland.
9. Eguchi, K., K. Kanazawa, Y. Eriguche, and Y. Veda. 2009. Pharmacodynamics of SMP-601(PTZ-601) against vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in neutropenic murine thigh infection models. Antimicrob. Agents Chemother. 53:3391-3398.
10. Livermore, D. M., S. Mushtaq, and M. Warner. 2009. Activity of the new anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J. Antimicrob. Chemother. 64:330-335.
11. MacGowan, A. P., C. A. Rogers, H. A. Holt, and K. E. Bowker. 2003. Activities of moxifloxacin against and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1088-1095.
12. MacGowan, A. P., K. E. Bowker, and A. R. Noel. 2008. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 52:1401-1406.
13. MacGowan, A. P., R. Reynolds, A. R. Noel, and K. E. Bowker. 2009. Bacterial strain-to-strain variation in the pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints. Antimicrob. Agents Chemother. 53:5181-5184.
14. Maglio, D., et al. 2005. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob. Agents Chemother. 49:276-280.
15. Noel, A. R., K. E. Bowker, S. G. Tomaselli, and A. P. MacGowan. 2008. Pharmacodynamics of doripenem against Pseudomonas aeruginosa and Acinetobacter spp., abstr. A-024, p. 6. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
16. Pace, J., et al. 2007. PZ-601 is active against both Gram-positive and Gram-negative bacterial pathogens caustic for complicated skin and skin structure infection in community acquired pneumonia, abstr. 1733-1166. Abstr. 17th Eur. Congr. Clin. Microbiol. Infect. Dis., Munich, Germany. www.blackwellpublishing.com/eccmid17/abstract.asp?id=57465.
17. Sugihara, K., et al. 2008. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and MRSA in a murine thigh infection model, abstr. A-027. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
18. Ueda, Y., et al.. 2005. In vitro and in vivo antibacterial activities of SM- 216601, a new broad-spectrum parenteral carbapenem. Antimicrob. Agents Chemother. 49:4185-4196.
19. Walker, R., D. R. Andes, S. Kiem, and W. A. Craig. 2003. In vivo pharmacodynamic activity of a new carbapenem doripenem against multiple bacteria in a murine thigh infection model, abstr. A-308, p. 10. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.